Phaseline

Targets › TSHR

TSHR (Thyrotropin receptor): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 1 Phase 3, 1 Phase 2; Oncology; next expected readout Jan 2030.

Receptor for the thyroid-stimulating hormone (TSH) or thyrotropin. Also acts as a receptor for the heterodimeric glycoprotein hormone (GPHA2:GPHB5) or thyrostimulin. (UniProt, P16473)

Open in Phaseline: the race on TSHR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Gustave Roussy, Cancer Campus, Grand ParisrhTSH stimulation (Thyrogen)
Recombinant human thyroid-stimulating hormone (TSH receptor agonist)
TSHRPhase 3Low Risk Differentiated Thyroid CancerJan 2030
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Thyrogen
Recombinant human TSH (rhTSH) to stimulate thyroid hormone production
TSHRPhase 2Thyroid CancerNov 2035

Conditions

Low Risk Differentiated Thyroid Cancer (1) Thyroid Cancer (1)

Modalities

small molecule (2)

Companies

Gustave Roussy, Cancer Campus, Grand Paris (1) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.